A novel population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B
Sjoerd F. Koopman1*, Tine M.H.J. Goedhart2*, Laura H. Bukkems1, Trevor M. Mulders1, Frank W.G. Leebeek3, Karin Fijnvandraat4, Michiel Coppens5,6, Mary Mathias7, Peter W. Collins8, R. Campbell Tait9, Catherine Bagot9, Nicola Curry10, Jeanette Payne11, Pratima Chowdary12, Marjon H. Cnossen2* & Ron A.A. Mathôt1*, for the OPTI-CLOT study group and SYMPHONY consortium.
1Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Centers, Amsterdam, The Netherlands;2Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children’s Hospital, University Medical Center Rotterdam; Rotterdam, The Netherlands; 3Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; 4Amsterdam UMC, University of Amsterdam, Emma Children’s Hospital, Pediatric Hematology, Amsterdam, The Netherlands; 5Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;6Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, The Netherlands;7Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom; 8Arthur Bloom Haemophilia Centre, School of Medicine, Cardiff University Hospital, Cardiff, United Kingdom;9Department of Haematology, Royal Infirmary, Glasgow, United Kingdom; 10Oxford Haemophilia and Thrombosis Centre and Oxford NIHR BRC, Nuffield Orthopaedic Hospital, Oxford, United Kingdom; 11Department of Paediatric Haematology, Sheffield Children’s NHS Foundation Trust, Sheffield, United Kingdom; 12Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom
*shared first and last authorships